Paprameters | n / x ± s |
---|---|
Gender | |
 Male | 101 |
 Female | 34 |
Age, years | 59.2 ± 10.8 |
Body mass index, kg/m^2 | 23.5 ± 3.6 |
ASA classification | |
 1 | 9 |
 2 | 102 |
 3 | 24 |
Side | |
 Left | 49 |
 Right | 86 |
Tumor diameter, cm | 8.8 ± 3.5 |
Tumor thrombus grade | |
 0 | 31 |
 I | 38 |
 II | 39 |
 III | 16 |
 IV | 11 |
Preoperative serum creatinine, µmol/L | 101.9 ± 78.2 |
Postoperative serum creatinine, µmol/L | 123.1 ± 121.6 |
Preoperative eGFR, mL/(min × 1.73 m^2) | 73.9 ± 21.8 |
Postoperative eGFR, mL/(min × 1.73 m^2) | 69.5 ± 25.2 |
Operation approach | |
 Laparoscopic approach | 74 |
 Open approach | 61 |
Ipsilateral adrenalectomy | |
 No | 59 |
 Yes | 76 |
T stage | |
 T3a | 27 |
 T3b | 83 |
 T3c | 7 |
 T4 | 18 |
Lymph node dissection | |
 No | 65 |
 Yes | 70 |
Vascular wall invasion | |
 No | 82 |
 Yes | 53 |
Operation time, min | 337.0 ± 122.7 |
Intraoperative hemorrhage, ml | 1387.7 ± 1640.6 |
Pathological type | |
 Clear cell carcinoma | 115 |
 Non clear cell carcinoma | 20 |
WHO/ISUP 2016 Nuclear classification | |
 1 | 3 |
 2 | 47 |
 3 | 51 |
 4 | 34 |
Lymph node metastasis | |
 No | 125 |
 Yes | 10 |
Metastasis or invasion of adrenal glands | |
 No | 117 |
 Yes | 18 |
Metastasis | |
 No | 100 |
 Yes | 35 |
Lymphatic vascular invasion | |
 No | 106 |
 Yes | 29 |
Perinephric tissues invasion | |
 No | 94 |
 Yes | 41 |
Renal pelvis invasion | |
 No | 105 |
 Yes | 30 |
Necrosis | |
 No | 66 |
 Yes | 69 |
Sarcomatoid differentiation | |
 No | 113 |
 Yes | 22 |
Postoperative complications | |
 No | 79 |
 Yes | 56 |
Serious complications | |
 No | 38 |
 Yes | 18 |